Lorenzo-Almoros A, Tunon J, Orejas M, Cortes M, Egido J, Lorenzo O. Diagnostic approaches for diabetic cardiomyopathy. Cardiovasc Diabetol. 2017;16(1):28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lorenzo-Almoros A, Cepeda-Rodrigo JM, Lorenzo O. Diabetic cardiomyopathy. Rev Clin Esp (Barc). 2022;222(2):100–11.

CAS  PubMed  Google Scholar 

Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, Kober L, McKelvie RS, Zile MR, Anand IS, et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-preserve trial (Irbesartan in Heart failure with preserved ejection fraction). Circulation. 2017;135(8):724–35.

Article  PubMed  Google Scholar 

Hu X, Bai T, Xu Z, Liu Q, Zheng Y, Cai L. Pathophysiological Fundamentals of Diabetic Cardiomyopathy. Compr Physiol. 2017;7(2):693–711.

Article  PubMed  Google Scholar 

Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a thrifty substrate hypothesis. Diabetes Care. 2016;39(7):1108–14.

Article  PubMed  Google Scholar 

Bertero E, Maack C. Metabolic remodelling in heart failure. Nat Rev Cardiol. 2018;15(8):457–70.

Article  CAS  PubMed  Google Scholar 

Taegtmeyer H. Failing heart and starving brain: ketone bodies to the rescue. Circulation. 2016;134(4):265–6.

Article  PubMed  PubMed Central  Google Scholar 

Mustroph J, Wagemann O, Lucht CM, Trum M, Hammer KP, Sag CM, Lebek S, Tarnowski D, Reinders J, Perbellini F, et al. Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail. 2018;5(4):642–8.

Article  PubMed  PubMed Central  Google Scholar 

Bertero E, Maack C. Calcium Signaling and reactive oxygen species in Mitochondria. Circ Res. 2018;122(10):1460–78.

Article  CAS  PubMed  Google Scholar 

Lambert R, Srodulski S, Peng X, Margulies KB, Despa F, Despa S. Intracellular na + concentration ([Na+]i) is elevated in Diabetic hearts due to enhanced Na+-Glucose cotransport. J Am Heart Assoc. 2015;4(9):e002183.

Article  PubMed  PubMed Central  Google Scholar 

Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: part I: general concepts. Circulation. 2002;105(14):1727–33.

Article  CAS  PubMed  Google Scholar 

Kruger M, Babicz K, von Frieling-Salewsky M, Linke WA. Insulin signaling regulates cardiac titin properties in heart development and diabetic cardiomyopathy. J Mol Cell Cardiol. 2010;48(5):910–6.

Article  PubMed  Google Scholar 

Packer M. Leptin-Aldosterone-Neprilysin Axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation. 2018;137(15):1614–31.

Article  CAS  PubMed  Google Scholar 

Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136(1):6–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gruzdeva OV, Akbasheva OE, Dyleva YA, Antonova LV, Matveeva VG, Uchasova EG, Fanaskova EV, Karetnikova VN, Ivanov SV, Barbarash OL. Adipokine and Cytokine profiles of Epicardial and Subcutaneous Adipose tissue in patients with Coronary Heart Disease. Bull Exp Biol Med. 2017;163(5):608–11.

Article  CAS  PubMed  Google Scholar 

Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2015;3(5):356–66.

Article  CAS  PubMed  Google Scholar 

Eriksson L, Nystrom T. Antidiabetic agents and endothelial dysfunction—beyond glucose control. Basic Clin Pharmacol Toxicol. 2015;117(1):15–25.

Article  CAS  PubMed  Google Scholar 

Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012;5(6):720–6.

Article  PubMed  PubMed Central  Google Scholar 

De Keulenaer GW, Brutsaert DL. Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation. 2011;123(18):1996–2004. discussion 2005.

Article  PubMed  Google Scholar 

Wang L, Lv Y, Li G, Xiao J. MicroRNAs in heart and circulation during physical exercise. J Sport Health Sci. 2018;7(4):433–41.

Article  PubMed  PubMed Central  Google Scholar 

Zhang W, Xu W, Feng Y, Zhou X. Non-coding RNA involvement in the pathogenesis of diabetic cardiomyopathy. J Cell Mol Med. 2019;23(9):5859–67.

Article  PubMed  PubMed Central  Google Scholar 

Duan Y, Zhou B, Su H, Liu Y, Du C. miR-150 regulates high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300. Exp Cell Res. 2013;319(3):173–84.

Article  CAS  PubMed  Google Scholar 

Chen S, Puthanveetil P, Feng B, Matkovich SJ, Dorn GW 2nd, Chakrabarti S. Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes. J Cell Mol Med. 2014;18(3):415–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li X, Du N, Zhang Q, Li J, Chen X, Liu X, Hu Y, Qin W, Shen N, Xu C, et al. MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy. Cell Death Dis. 2014;5(10):e1479.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ikeda S, He A, Kong SW, Lu J, Bejar R, Bodyak N, Lee KH, Ma Q, Kang PM, Golub TR, et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol. 2009;29(8):2193–204.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feng B, Chen S, George B, Feng Q, Chakrabarti S. miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab Res Rev. 2010;26(1):40–9.

Article  CAS  PubMed  Google Scholar 

Shen E, Diao X, Wang X, Chen R, Hu B. MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy. Am J Pathol. 2011;179(2):639–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raut SK, Singh GB, Rastogi B, Saikia UN, Mittal A, Dogra N, Singh S, Prasad R, Khullar M. miR-30c and miR-181a synergistically modulate p53-p21 pathway in diabetes induced cardiac hypertrophy. Mol Cell Biochem. 2016;417(1–2):191–203.

Article  CAS  PubMed  Google Scholar 

Raut SK, Kumar A, Singh GB, Nahar U, Sharma V, Mittal A, Sharma R, Khullar M. miR-30c mediates Upregulation of Cdc42 and Pak1 in Diabetic Cardiomyopathy. Cardiovasc Ther. 2015;33(3):89–97.

Article  CAS  PubMed  Google Scholar 

Florczyk-Soluch U, Polak K, Sabo R, Martyniak A, Stepniewski J, Dulak J. Compromised diabetic heart function is not affected by miR-378a upregulation upon hyperglycemia. Pharmacol Rep. 2023;75(6):1556–70.

Article  CAS